Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Translational research

1929O - Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients

Date

19 Sep 2020

Session

Proffered Paper - Translational research

Topics

Translational Research

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Giulia Mazzaschi

Citation

Annals of Oncology (2020) 31 (suppl_4): S1034-S1051. 10.1016/annonc/annonc294

Authors

G. Mazzaschi1, R. Minari2, V. Ferri1, P. Bordi2, L. Gnetti3, M. Bersanelli4, A. Cavazzoni5, S. Buti2, A. Leonetti2, A. Zecca6, A. Cosenza2, L. Ferri2, E. Rapacchi1, C. Mori6, P.G. Petronini5, G. Missale6, F. Quaini5, M. Tiseo2

Author affiliations

  • 1 Medical Oncology, University Hospital of Parma, 43126 - Parma/IT
  • 2 Medical Oncology Unit, University Hospital of Parma, 43126 - Parma/IT
  • 3 Pathology Unit, University Hospital of Parma, 43126 - Parma/IT
  • 4 Medical Oncology, Azienda Ospedaliera di Parma, 43126 - Parma/IT
  • 5 Medicine And Surgery, University Hospital of Parma, 43126 - Parma/IT
  • 6 Infectious Disease Unit, University Hospital of Parma, 43126 - Parma/IT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1929O

Background

Upfront criteria to foresee immune checkpoint inhibitors (ICI) efficacy are far from being identified. Thus, we integrated blood descriptors of pro-inflammatory/immunosuppressive or effective anti-tumor response to define predictive immune profiles in ICI-treated advanced NSCLC.

Methods

Peripheral blood (PB) was prospectively collected at baseline from 109 consecutive NSCLC patients undergoing ICI as first or more line treatment. Soluble PD-L1 (sPD-L1) (immunoassay), CD8+PD1+ and NK cells (FACS) were assessed and integrated to generate an Immune effector Score (IeffS). Lung Immune Prognostic Index (LIPI) was also computed by LDH levels and derived Neutrophil-to-Lymphocyte Ratio (dNLR). All these parameters were correlated with survival outcome and response to treatment.

Results

High sPD-L1 and low PB number of CD8+PD1+ and NK cells, individually had a negative impact on both PFS (P<0.001) and OS (P<0.01) as well as on ICI-response (P<0.05). Thus, sPD-L1high, CD8+PD1+low and NKlow were considered as risk factors encompassing IeffS, whose prognostic power outperformed that of single features and slightly exceeded that of LIPI. Accordingly, the absence of these pre-determined risk factors portrayed a favorable IeffS able to identify NSCLC patients with significantly prolonged PFS (median NR vs 2.3 months, P<0.001) and OS (median NR vs 4.1, P<0.001) and greater benefit from ICI (P<0.01). We then combined each individual risk parameter composing IeffS and LIPI (LDHhigh, dNLRhigh), thus defining three distinct prognostic classes: 0-1 vs 2-3 vs ≥ 4 risk factors. A remarkable impact of IeffS-LIPI integration was documented in terms of survival outcome (PFS: HR, 4.61; 95% CI, 2.32-9.18; P<0.001; OS: HR, 4.03; 95% CI, 1.91-8.67; P<0.001) and response to ICI (ROC curve AUC=0.90, 95% CI 0.81-0.97, P<0.001).

Conclusions

Composite risk models based on blood parameters featuring the tumor-host interaction might provide non-invasive prognostic and predictive scores in ICI-treated advanced NSCLC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

University Hospital of Parma.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.